HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 01, January 2019 – Taiwan medical tourism - Combining medical travel and tourist destination       » New breast cancer drug now available in China       » Chinese scientists make important cancer finding       » Japan's plan to revolutionise healthcare sector with tech       » GSK to buy oncology drugmaker Tesaro for US$5.1 billion       » There is hope for anticancer vaccines      
INSIDE INDUSTRY
A new treatment to lose weight and keep it off
Novo Nordisk launches a new obesity treatment: Saxenda

A new injectable medicine is in the market to help overweight and obese people lose weight. Novo Nordisk’s Saxenda (liraglutide 3.0 mg) is a once-daily glucagon-like peptide-1 (GLP-1) analogue with 97 percent similarity to naturally occurring human GLP-1, a hormone that is released in response to food intake. Saxenda regulates appetite by increasing feelings of fullness and satiety, while lowering feelings of hunger and prospective food consumption, thereby leading to lower calorie intake and weight loss.

Saxenda when used alongside a low-calorie meal plan and increased physical activity, helps adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2 to <30 kg/m²) with at least one weight-related medical problem (such as high blood pressure, high cholesterol, or type 2 diabetes or, prediabetes, or obstructive sleep apnea) to lose weight.

As with other GLP-1 receptor agonists, Saxenda stimulates insulin secretion and lowers glucagon secretion in a glucose-dependent manner. These effects can lead to a reduction of fasting and post-prandial blood glucose for those with diabetes.

The efficacy of Saxenda as a weight loss agent has been conducted in four clinical trials involving more than 5000 patients. Saxenda has been approved by Health Sciences Authority (HSA), Singapore. It is also approved by the US Food and Drug Administration (FDA) and the European Commission (EC).

Saxenda is available in 33 countries, including Australia, South Korea, US and UK.

Click here for the complete issue.

NEWS CRUNCH  
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy